RAIN News and Press, Rain Therapeutics Inc. From 08/11/21

Image source: The Motley Fool. Rain Therapeutics (NASDAQ: RAIN) Q2 2021 Earnings Call Aug 10, 2021 , 4:30 p.m. ET Continue reading For further details see: Rain Therapeutics (RAIN) Q2 2021 Earnings Call Transcript

Rain Therapeutics, Inc. (RAIN) Q2 2021 Earnings Conference Call August 10, 2021 4:30 PM ET Company Participants Glenn Garmont - LifeSci Advisors, Investor Relations Avanish Vellanki - Chief Executive Officer Richard Bryce - Chief Medical Officer Bob Doebele - Chief Scientific Officer Nelson C...

First patient dosed in Phase 3 registrational trial (MANTRA) evaluating milademetan (RAIN-32) in patients with dedifferentiated (“DD”) liposarcoma (“LPS”) Quarter-end cash position of $164.6 million provides runway through late 2024 Management...

NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on ...

Rain Therapeutics (RAIN) announces that the first patient has been randomized in the late-stage study evaluating milademetan (RAIN-32) for the treatment of de-differentiated  liposarcoma ((DD LPS)), a rare from of cancer.The trial is a randomized, multicenter, open-label, ...

The randomized, multi-center, open-label Phase 3 trial will evaluate the efficacy and safety of milademetan in patients with de-differentiated (DD) liposarcoma (LPS) Multiple patients with liposarcoma have demonstrated long-term therapy with milademetan monotherapy now exceeding...

DavidBGray/E+ via Getty Images Rain Therapeutics ([[RAIN]] +5.9%) after 10% owner and director BVF PARTNERS L P/IL buys 587,002 shares indirectly on July 1st at an average price of $15.25 - $15.65 for a total outlay of ~ $9.1M. A quick look at the company's ...

NEWARK, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced a master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intel...

NEWARK, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced a patient referral partnership with Caris Life Sciences (“Caris”). Under the terms of the ...

NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present a corporate over...